Press brief by James N. Kochenderfer, MD, at the American Socitety of Hematology (ASH) 2015 annual meeting. Dr Kochenderfer provides an overview of a trial of allogeneic T-cells that were genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19.
Infusion of allogeneic anti-CD19 CAR T-cells is a promising approach after alloHSCT
12th December 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now